XBiotech Announces First Patient Enrolled Into The French National Cancer Institute Sponsored Phase I/II/III Clinical Study For Natrunix Therapy For Colorectal Cancer
XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
XBiotech Sponsored Study Titled ‘Natrunix Versus Methotrexate in Rheumatoid Arthritis’ Posted To ClinicalTrials.gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05363917